# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ: ALZN) with a Buy and lowers the price target from $4...
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0....
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $18...
Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims fo...